(Q44019265)

29 November 2017

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy (English)

1 reference

29 November 2017

0 references

1 reference

Anthony V D'Amico

1

1 reference

29 November 2017

Judd W Moul

2

1 reference

29 November 2017

Peter R Carroll

3

1 reference

29 November 2017

Leon Sun

4

1 reference

29 November 2017

Deborah Lubeck

5

1 reference

29 November 2017

Ming-Hui Chen

6

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

Journal of the National Cancer Institute

29 November 2017

1 reference

29 November 2017

95

1 reference

29 November 2017

1376-1383

1 reference

29 November 2017

18

1 reference

Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database

29 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

Estimating the proportion of treatment effect explained by a surrogate marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

Surrogate end points in clinical trials: are we being misled?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

Meta-analysis for the evaluation of potential surrogate markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

Criteria for the validation of surrogate endpoints in randomized experiments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJG043

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJG043

1 reference

29 November 2017

1 reference